The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Europe down but oil and mining stocks boost FTSE

Wed, 23rd Jun 2021 12:11

(Alliance News) - The FTSE 100 climbed midday Wednesday, with share price gains for miners and oil stocks ensuring the London's blue-chip index outperformed continental peers, following a raft of mixed PMI readings across the globe.

"Experiences throughout Australia, Japan, and Europe highlight a tough June after many surveys fell short. From a UK perspective, the decline in services growth is worrying, with exports falling for the second-consecutive month," IG market analyst Joshua Mahony commented.

"From a UK perspective, the decline in services growth is worrying, with exports falling for the second-consecutive month. One common theme appears to be the impact of rising prices, with input costs rising at the fastest pace in 13 years."

The FTSE 100 index was up 24.87 points, or 0.4%, at 7,114.88 on Wednesday at midday. The mid-cap FTSE 250 index was up just 8.18 points 22,687.82. The AIM All-Share index was up 2.70 points, or 0.2%, at 1,224.85.

The Cboe UK 100 index was up 0.3% at 708.55. The Cboe 250 was 0.1% higher at 20,378.93, and the Cboe Small Companies up 0.4% at 15,348.99.

The UK's flash composite output index, a weighted average of the services and manufacturing readings, remained above the 50.0 no-change mark but fell to a two-month low of 61.7 points in June, from May's 62.9 tally.

Earlier figures showed Japan's private sector remained in contraction, though the eurozone's flash composite PMI increased to 59.2 in June from 57.1 in May, its highest since June 2006.

The pound was quoted at USD1.3967 midday Wednesday following the PMI data, up from USD1.3927 at the London equities close on Tuesday. The euro stood at USD1.1946, up from USD1.1905.

In mainland Europe, the CAC 40 in Paris was down 0.4%, while the DAX 30 in Frankfurt was down 0.5%.

The luxury retail sector held back the blue-chip benchmark in Paris. Kering was down 2.6%, Hermes International 1.6% lower and LVMH fell 1.3%.

In London, Burberry was down 0.1% after HSBC cut the stock to Hold from Buy.

Brent oil was quoted at USD75.44 a barrel, up from USD74.91.

ActivTrades analyst Pierre Veyret explained: "Most oil traders are also paying attention to the ongoing talks with Iran where an agreement with another superpower could quickly lead to a flood in global supply and seriously dent the current rally. Investors will also keep an eye on today's US crude oil inventories where a significant increase is widely expected."

Royal Dutch Shell A shares rose 1.8% in London and the oil major's B stock was up 1.9%. In addition, Societe Generale raised Shell's A shares to Buy from Hold. Peer BP was trading 1.3% higher.

Rio Tinto climbed 1.0%, Anglo American was up 1.1% and BHP rose 0.7% during a largely positive session for the mining sector.

Phoenix Group shares fell 3.3% to 670.20p, the worst blue-chip performer in London. Swiss Re said it has sold a 6.6% stake in Phoenix Group for GBP437 million, offloading half the stake it acquired after selling its ReAssure Group subsidiary to Phoenix last summer.

Swiss Re sold 66.2 million shares at 660p each, and will hold a 6.6% stake following completion of the sale. Prior to the transaction, Swiss Re held a near 13.3% stake in Phoenix Group.

Phoenix was not a party to the placing and will not receive any proceeds.

As Swiss Re's stake has fallen below 10%, it no longer has the right to appoint a non-executive director to the Phoenix board, the FTSE 100-listed long-term savings and retirement business noted. As a result, Christopher Minter will resign from the Phoenix board with effect from the share sale settlement, expected to be around June 25.

The housebuilding sector was lower. Barratt Developments fell 1.7%, Taylor Wimpey gave back 1.4% and Persimmon fell 1.6%.

The UK Competition & Markets Authority said Persimmon and insurer Aviva have committed to refund leasehold homeowners following an industry probe.

Persimmon will allow homeowners to buy the freehold of their home at a discount, while Aviva will remove certain clauses from leasehold contracts and repay those who were affected by them, the regulator said.

Persimmon said all homeowners who have bought a leasehold property since 2000 will be allowed to buy their freehold, for a price capped at GBP2,000. The company also will reimburse customers who already bought their freehold for more than GBP2,000 under an existing scheme.

Aviva, which buys leasehold contracts from housebuilders, has agreed to remove "doubling clauses" and refund those who were affected by them. It will also end ground rents that rise with inflation, meaning those rents will revert to their original price.

Aviva shares were 0.1% lower.

Berkeley fell 1.8%, despite reporting improved annual earnings. The housebuilder cautioned transaction levels in its key London market were hit by travel restrictions and Berkeley's selective approach to market, but was confident as enquiries in the UK capital are now above pre-pandemic levels.

Berkeley's pretax profit in the year ended April 30 was 2.9% higher at GBP518.1 million from GBP503.7 million. Revenue rose 15% to GBP2.20 billion from GBP1.92 billion.

GlaxoSmithKline shares were on the rise, up 1.6%. The pharmaceutical firm outlined a new strategic focus, plans to boost sales and profit in the medium term and a fresh "progressive dividend policy".

In an investor update, GSK said it plans to achieve GBP33 billion in sales by the end of 2031. Over the next five years, it is eyeing a sales climb of more than 5% and more than a 10% hike in adjusted operating profit.

It added it will retain a 20% stake in its upcoming Consumer Healthcare spin-out, a "short-term financial investment, which it intends to monetise in a timely manner".

New York equities are called higher, building on Tuesday's gains. The Dow Jones Industrial Average is called up 0.2%, and both the S&P 500 and Nasdaq Composite are pointed up 0.1%. Federal Reserve Chair Jerome Powell on Tuesday suggested the central bank will only patiently rein in its vast monetary policy support.

Powell stuck to his prepared script during the House hearing and reiterated that the central bank will continue its supportive stance to ensure that the "sustained improvement" since the depths of Covid-19 pandemic is extended.

BDSwiss head of investment research, Marshall Gittler, commented: "Powell didn't say anything different from what he said in his comments after the FOMC meeting: most of the rise in inflation is due to transitory effects arising from the reopening of the economy, but these effects have been larger than they expected and could turn out to be more persistent. He emphasized that the FOMC 'will wait for actual evidence of actual inflation or other imbalances' before hiking rates and not move in response to projections."

Against the yen, the dollar was trading at JPY111.04, up from JPY110.73.

Gold was trading at USD1,783.29 an ounce midday on Wednesday, up against USD1,780.60 late Tuesday.

Wednesday afternoon's economic calendar has the US flash PMI for June at 1445 BST, before new home sales at 1500 BST.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.